Literature DB >> 22424612

Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists.

Maikel Wijtmans1, David Maussang, Francesco Sirci, Danny J Scholten, Meritxell Canals, Azra Mujić-Delić, Milagros Chong, Kristell L S Chatalic, Hans Custers, Elwin Janssen, Chris de Graaf, Martine J Smit, Iwan J P de Esch, Rob Leurs.   

Abstract

The chemokine receptor CXCR7 is an atypical G protein-coupled receptor as it preferentially signals through the β-arrestin pathway rather than through G proteins. CXCR7 is thought to be of importance in cancer and the development of CXCR7-targeting ligands is of huge importance to further elucidate the pharmacology and the therapeutic potential of CXCR7. In the present study, we synthesized 24 derivatives based on a compound scaffold patented by Chemocentryx and obtained CXCR7 ligands with pK(i) values ranging from 5.3 to 8.1. SAR studies were supported by computational 3D Fingerprint studies, revealing several important affinity descriptors. Two key compounds (29 and 30, VUF11207 and VUF11403) were found to be high-potency ligands that induce recruitment of β-arrestin2 and subsequent internalization of CXCR7, making them important tool compounds in future CXCR7 research.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22424612     DOI: 10.1016/j.ejmech.2012.02.041

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  22 in total

1.  Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel β-Arrestin Antagonist Activity.

Authors:  Elnaz Menhaji-Klotz; Jessica Ward; Janice A Brown; Paula M Loria; Carina Tan; Kevin D Hesp; Keith A Riccardi; John Litchfield; Markus Boehm
Journal:  ACS Med Chem Lett       Date:  2020-05-14       Impact factor: 4.345

2.  Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.

Authors:  David Maussang; Azra Mujić-Delić; Francis J Descamps; Catelijne Stortelers; Peter Vanlandschoot; Marijke Stigter-van Walsum; Henry F Vischer; Maarten van Roy; Maria Vosjan; Maria Gonzalez-Pajuelo; Guus A M S van Dongen; Pascal Merchiers; Philippe van Rompaey; Martine J Smit
Journal:  J Biol Chem       Date:  2013-08-26       Impact factor: 5.157

3.  Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Authors:  Martyna Szpakowska; Amanda M Nevins; Max Meyrath; David Rhainds; Thomas D'huys; François Guité-Vinet; Nadine Dupuis; Pierre-Arnaud Gauthier; Manuel Counson; Andrew Kleist; Geneviève St-Onge; Julien Hanson; Dominique Schols; Brian F Volkman; Nikolaus Heveker; Andy Chevigné
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

4.  Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of the Rho-associated kinase via the Cxcl12/Cxcr4 signaling axis.

Authors:  Chie Onishi; Chie Onish; Satomi Mori-Kimachi; Tomohiro Hirade; Mariko Abe; Takeshi Taketani; Junji Suzumiya; Toshitsugu Sugimoto; Seiji Yamaguchi; Reuben Kapur; Seiji Fukuda
Journal:  J Biol Chem       Date:  2014-09-18       Impact factor: 5.157

5.  Small Molecule-mediated Insulin Hypersecretion Induces Transient ER Stress Response and Loss of Beta Cell Function.

Authors:  Karina Rodrigues-Dos-Santos; Gitanjali Roy; Derk D Binns; Magdalena G Grzemska; Luiz F Barella; Fiona Armoo; Melissa K McCoy; Andy V Huynh; Jonathan Z Yang; Bruce A Posner; Melanie H Cobb; Michael A Kalwat
Journal:  Endocrinology       Date:  2022-07-01       Impact factor: 5.051

Review 6.  Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases.

Authors:  Vincent Duval; Paul Alayrac; Jean-Sébastien Silvestre; Angélique Levoye
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

7.  Detailed analysis of biased histamine H₄ receptor signalling by JNJ 7777120 analogues.

Authors:  S Nijmeijer; H F Vischer; F Sirci; S Schultes; H Engelhardt; C de Graaf; E M Rosethorne; S J Charlton; R Leurs
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

8.  Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.

Authors:  Martin Gustavsson; Douglas P Dyer; Chunxia Zhao; Tracy M Handel
Journal:  Sci Signal       Date:  2019-09-10       Impact factor: 8.192

9.  Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.

Authors:  Anna Ehrlich; Paramita Ray; Kathryn E Luker; Elias J Lolis; Gary D Luker
Journal:  Biochem Pharmacol       Date:  2013-08-22       Impact factor: 5.858

Review 10.  CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.

Authors:  Roberto Würth; Adriana Bajetto; Jeffrey K Harrison; Federica Barbieri; Tullio Florio
Journal:  Front Cell Neurosci       Date:  2014-05-28       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.